Antiretroviral therapy for HIV infection: Promises and problems

JAMA

Volumn 279, Issue 17, 1998, Pages 1343-1344

  Volberding, Paul A ^a,b,c,d   Deeks, Steven G ^a,b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Agouron

^d Merck

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ACUTE DISEASE; CHRONIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; LYMPHOCYTE COUNT; METABOLIC DISORDER; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0032490145     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.17.1343     Document Type: Short Survey

References (15)

1. Finzi D, Hermankova MK, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295-1300.
2. + T cell responses associated with control of viremia. Science. 1997; 278;1447-1450.
3. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
4. Gulick R, Mellors J, Havlir D, et al. Indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC): concurrent or sequential therapy in ZDV-experienced patients. In: Program and abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract I-89.
5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infections and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997; 337:725-733.
6. Carpenter CC, Fischl M, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1997;277:1962-1969.
7. US Department of Health and Human Services, Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. November 5, 1997 document. Available at: http://www.hivatis .org/upguidaa.html. Accessed March 26, 1998.
8. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278:1291-1295.
9. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection. Nature Med. 1998;4:208-214.
10. Connick E, Lederman M, Kotzin B, et al. Immunologic effects of 48 weeks of AZT/3TC/ritonavir. In: Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 778/Late Breaker 14. Available from: http://www.retroconference.org. Accessed March 26, 1998.
11. Demeter L, Hughes M, Fischl M, et al. Predictors of virologic and clinical responses to indinavir (IDV)+ZDV+3TC or ZDV+3TC. In: Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 509/Session 66. Available at: http://www.retroconference.org. Accessed March 26, 1998.
12. Deeks S, Loftus R, Cohen P, Chin S, Grant R. Incidence and predictors of virologic failure of indinavir and/or ritonavir in an urban health clinic. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract LB-02.
13. Hecht FM, Colfax G, Swanson M, Chesney MA. Adherence and effectiveness of protease inhibitors in clinical practice. In: Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 151/Session 24. Available at: http://www .retroconference.org. Accessed March 26, 1998.
14. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 1998;351:867-870.
15. Denning P, Fleming P, Viral Load Project Group. Beyond clinical trials: population-based HIV viral load monitoring and antiretroviral therapy. In: Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 11/Session 6. Available at: http://www.retroconference.org. Accessed March 26, 1998.